Just a note that if successful this drug will bring in more revenue than Daybue for Retts - essentially doubles plus our value on this indication alone.
Ann: P2 trial shows significant improvements in Phelan-McDermid, page-56
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.33 |
Change
-0.210(1.67%) |
Mkt cap ! $1.534B | |||
| Open | High | Low | Value | Volume |
| $12.45 | $12.45 | $11.88 | $4.938M | 405.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 7 | $12.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.34 | 676 | 8 |
View Market Depth
| Last trade - 14.59pm 23/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |